Marleen Coronel
Internal Medicine · Fresno, CANPI 1417100322
Payments from drug & device makers
Across 60 payments — averaging $16.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$166
- GSK$109
- Akcea Therapeutics, Inc.$98
- Boehringer Ingelheim$87
- Johnson & Johnson$83
- Abbott$51
- plus $409 from 16 others
What the payments were for
- Food & beverage$99799%
- Education$61%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 13 | $166 |
| GSK | 7 | $109 |
| Akcea Therapeutics, Inc. | 3 | $98 |
| Boehringer Ingelheim | 5 | $87 |
| Johnson & Johnson | 3 | $83 |
| Abbott | 3 | $51 |
| AbbVie(2 entities) | 3 | $45 |
| Boston Scientific | 2 | $41 |
| Lilly USA, LLC | 3 | $38 |
| Sanofi-aventis U.S. LLC | 2 | $38 |
| Astellas Pharma US Inc | 2 | $33 |
| Pfizer | 2 | $30 |
| Novo Nordisk | 2 | $29 |
| Amgen | 1 | $29 |
| Arbor Pharmaceuticals, Inc. | 2 | $25 |
| Pacira Therapeutics, Inc. | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $14 |
| Edwards Lifesciences | 1 | $13 |
| Nabriva Therapeutics, PLC | 1 | $11 |
How this compares
$1,003 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PromactaEltrombopag Olamine | 13 | $95,070 |
| JardianceEmpagliflozin | 130 | $75,963 |
| JanuviaSitagliptin Phosphate | 127 | $69,660 |
| DapagliflozinDapagliflozin Propanediol | 85 | $44,933 |
| Atorvastatin Calcium | 598 | $31,756 |
| Icosapent Ethyl | 138 | $31,104 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 46 | $30,884 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 26 | $27,386 |
| TrulicityDulaglutide | 24 | $24,834 |
| InvokanaCanagliflozin | 40 | $24,190 |
| RybelsusSemaglutide | 23 | $22,648 |
| LinzessLinaclotide | 32 | $17,718 |
| Ezetimibe | 166 | $15,960 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 61 | $15,740 |
| JanumetSitagliptin Phos/Metformin Hcl | 26 | $14,236 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta | $87 | $89,516156 claims |
| Novo NordiskXultophy 100-3.6, Rybelsus, Ozempic | $29 | $63,82063 claims |
| GSKTrelegy Ellipta | $109 | $30,88446 claims |
| Lilly USA, LLCTrulicity | $38 | $24,83424 claims |
| Johnson & JohnsonInvokana | $83 | $24,19040 claims |
| AbbVieLinzess | $45 | $17,71832 claims |
| PfizerEliquis | $30 | $12,81723 claims |
| Astellas Pharma US IncMyrbetriq | $33 | $8,52120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Fresno
- Andrew ChengSouth San Francisco$55.1M
- Joel NeutelTustin$34.9M
- Donald BrandonSan Diego$34M
- William TownerLos Angeles$27.4M
- Rahul AggarwalSan Francisco$24M
- Masoud AzizadNorthridge$21.1M
- Helen StaceyWalnut Creek$20.4M
- Rohit Loombala Jolla$15.1M
- Zeid KayaliColton$14.2M
- Alexandra DrakakiSanta Monica$14.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.